Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 1

Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells

Probukolün Lösemi, Multipl Miyeloma, Lenfoma ve Fibroblast Hücre Hatlarının Proliferasyonu Üzerindeki Etkileri

Pages
75–79
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key words: Probucol, chronic myeloid leukemia, multiple myeloma, histiocytic lymphoma, acute myeloid leukemia

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Probucol is a bisphenol antioxidant with antiinflammatory, antilipidemic and antidiabetic effect.
📊
Key Findings & Data:Materials and Methods: Different concentrations of probucol solutions were prepared and applied to the following cancer cell lines: K562S (imatinib sensitive) and K562R (imatinib resistant) chronic myeloid leukemia (CML) cells; U937 histiocytic lymphoma cells; HL60 acute myeloid leukemia cells; U266, H929, and RPMI8226 multiple myeloma cells; and L929 fibroblast cells.
💡
Conclusion & Impact:Key words: Probucol, chronic myeloid leukemia, multiple myeloma, histiocytic lymphoma, acute myeloid leukemia
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Probucol is a bisphenol antioxidant with antiinflammatory, antilipidemic and antidiabetic effect. Development and progression of cancer is closely related to chronic inflammation and oxidative stress. Agents that target these processes have been shown to modulate cancer cell proliferation. In this regard, the effect of probucol on proliferation of different cancer cell lines was investigated. Materials and Methods: Different concentrations of probucol solutions were prepared and applied to the following cancer cell lines: K562S (imatinib sensitive) and K562R (imatinib resistant) chronic myeloid leukemia (CML) cells; U937 histiocytic lymphoma cells; HL60 acute myeloid leukemia cells; U266, H929, and RPMI8226 multiple myeloma cells; and L929 fibroblast cells. Cell viability was conducted by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay. Results: Significant toxicity was not exhibited due to probucol treatment (0.1-10 µM) in K562S and K562R CML cells, U937 histiocytic lymphoma cells, HL60 acute myeloid leukemia cells, U266 multiple myeloma cells, and L929 fibroblast cells. However, probucol treatment significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells at the concentration of 0.5-10 µM and 5-10 µM, respectively. Conclusion: Probucol treatment slightly inhibited the viability of other cancer cell lines, but significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells. However, its effect was not potent, since a 50% reduction in cell viability could not be achieved at the concentrations of probucol treatment administered. Key words: Probucol, chronic myeloid leukemia, multiple myeloma, histiocytic lymphoma, acute myeloid leukemia

Özet

Amaç: Probukol, antiinflamatuvar, antilipidemik ve antidiyabetik aktivitelere sahip bisfenol bir antioksidandır. Kanser gelişimi ve ilerlemesi kronik inflamasyon ve oksidatif stres ile yakından ilişkilidir ve bu süreçleri hedefleyen ajanların kanser hücre proliferasyonunu modüle ettikleri gösterilmiştir. Bu bağlamda, bu çalışmada, probukolün farklı kanser hücre hatlarının proliferasyonu üzerindeki etkileri araştırılmıştır. Gereç ve Yöntemler: Probukolün farklı konsantrasyonlarda hazırlanan çözeltileri kullanılarak K562S (imatinib duyarılı), K562R (imatinib dirençli) kronik miyeloid lösemi (KML), U937 histiositik lenfoma, HL60 akut miyeloid lösemi, U266 multipl miyeloma ve L929 fibroblast hücre hatlarında hücre canlılığı 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium testi ile belirlenmiştir. Bulgular: Probukol uygulaması (0,1 µM-10 µM), K562S, K562R KML, U937 histositik lenfoma, HL60 akut miyeloid lösemi, U266, H929, RPMI8226 multipl miyelom ve L929 fibroblast hücre hatlarında anlamlı bir etki göstermemiştir. Diğer taraftan, probukol uygulaması, H929 ve RPMI8226 hücre serilerinin canlılığını sırasıyla 0,5-10 µM and 5-10 µM konsantrasyon aralığında anlamlı olarak azaltmıştır (p

🔖

Cite This Article

KOÇ, A., KARABAY, A. Z., YAPRAK, A., BÜYÜKBİNGÖL, Z., AKTAN, F. (2022). Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 1, 75–79. https://ajindex.com/articles/613629

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Heel RC, RN Brogden, TM Speight, GS Avery. Probucol: A review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs. 1978;15:409-428
  2. Buckley MM, KL Goa, AH Price, RN Brogden. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989;37:761-800
  3. Parthasarathy S, SG Young, JL Witztum, RC Pittman, D Steinberg. Probucol inhibits oxidative modification of low density lipoprotein. The Journal of clinical investigation. 1986;77:641-644
  4. Yamashita S, D Masuda, Y Matsuzawa. Did we abandon probucol too soon? Current opinion in lipidology.2015;26:304-316
  5. Takechi R, MM Pallebage-Gamarallage, V Lam, C Giles, JC Mamo. Longterm probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. Lipids in health and disease. 2014;13:91
  6. Keyamura Y, C Nagano, M Kohashi, M Niimi, M Nozako, T Koyama, R Yasufuku, A Imaizumi, H Itabe, T Yoshikawa. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. PloS one. 2014;9:e96929
  7. Mamo JC, V Lam, E Brook, A Mooranian, H Al-Salami, N Fimognari, M Nesbit, R Takechi. Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes & vascular disease research. 2019;16:87-97
  8. Ribeiro RP, EL Moreira, DB Santos, D Colle, AA Dos Santos, KC Peres, CP Figueiredo, M Farina. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson’s disease. Neurochemical Research. 2013;38:660-668
  9. Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, Farina M. Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. PLoS One. 2013;14;8:e67658
  10. Mooranian A, Zamani N, Luna G, Al-Sallami H, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. Bile acid-polymerprobucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model. Pharm Dev Technol. 2019;24:1272-1277
  11. Zucoloto AZ, Manchope MF, Borghi SM, Dos Santos TS, Fattori V, Badaro-Garcia S, Camilios-Neto D, Casagrande R, Verri WA Jr. Probucol Ameliorates Complete Freund’s Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation. Inflammation. 2019;42:1474-1490
  12. Snezhkina